Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Environment

ChemDiv Partners With Russia, U.S.

October 1, 2007 | A version of this story appeared in Volume 85, Issue 40

ChemDiv's Chemical Diversity Research Institute is joining with the Blokhin Russian Oncology Center, the Department of Energy, and the National Cancer Institute to develop small-molecule therapies for prostate cancer. The partnership will operate under DOE's Global Initiatives for Proliferation Prevention Program, which is designed to identify and invest in high-tech resources in the former Soviet Union. The initial two-year partnership has received financial commitments of about $1 million.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.